Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 20.92 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 5.39 | Oscillator | Buy |
| Williams %R (14) | -93.24 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.09 (Hist -0.02) | Oscillator | Strong Sell |
| Average Directional Index (14) | 33.46 (+DI 7.5 / -DI 37.5) | Trend | Strong Sell |
Current price $0.5669
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 15, 26 |
| EMA 20 | 0.73 | MA | Strong Sell |
| SMA 20 | 0.77 | MA | Strong Sell |
| EMA 50 | 0.86 | MA | Strong Sell |
| SMA 50 | 0.86 | MA | Strong Sell |
| SMA 200 | 1.17 | MA | Strong Sell |
| BTIG |
| maintain |
| Buy |
| Buy |
| Aug 7, 26 | Leerink Partners | downgrade | Outperform | Market Perform |
| Jul 1, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Apr 7, 26 | BTIG | maintain | Buy | Buy |
| Feb 25, 26 | BTIG | maintain | Buy | Buy |
| Feb 6, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Feb 6, 26 | Piper Sandler | maintain | Overweight | Overweight |
| Dec 2, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Dec 2, 25 | BTIG | maintain | Buy | Buy |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 6, 26 | Butler John P. | director, officer: CEO and President | M-Exempt | 350,000 @ $0.63 | $220.5K |
| Aug 6, 26 | Butler John P. | director, officer: CEO and President | M-Exempt | 350,000 @ $0.63 | $220.5K |
| Jun 29, 26 | Ostrowski Erik | officer: SVP, CFO, CBO & Treasurer | S-Sale | 56,019 @ $1.11 | $62.18K |
| Jun 17, 26 | Wolf Myles | director | A-Award | 35,700 | — |
| Jun 17, 26 | Wolf Myles | director | A-Award | 53,600 @ $1.02 | $54.67K |
| Jun 17, 26 | Smith Cynthia | director | A-Award | 35,700 | — |
| Jun 17, 26 | Smith Cynthia | director | A-Award | 53,600 @ $1.02 | $54.67K |
| Jun 17, 26 | Rogers Michael W | director | A-Award | 35,700 | — |
FY2025 · 10-K disclosure
TTM vs. 5-year historical average (annual ratios)
| Metric | AKBA | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -5.2x | -18.0x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -4.0x | EPS est. -0.14 | Discount |
| Price / Book | 6.1x | 4.4x | Elevated |
| Price / Sales | 0.7x | 1.5x | Discount |
| EV / EBITDA | -3.0x | -3.8x | Discount |
| Return on equity | -93.7% | — | Weak |
| Gross margin | 79.5% | 71.9% | In line |
| Debt / Equity | 2.16 | 4.20 | Levered |
| Piotroski / Altman Z | 3/9 | Z -5.85 | Distress |
Discounted cash flow model
Stock news · updated daily
WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, Dr. Steven Burke, Chief R&D and Medical Officer, and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in one-on-one meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026.
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced upcoming presentations at the American Society of Nephrology Kidney Week 2026 (ASN Kidney Week), which will take place in Denver, CO from October 21-25, 2026.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -0.04 | -0.02 | Beat 52.4% | $49.13M |
| May 7, 2026 | -0.01 | -0.03 | Miss -200.0% | $53.54M |
| Feb 26, 2026 | -0.03 | -0.05 | Miss -66.7% | $57.62M |
| Nov 10, 2025 | -0.06 | 0.00 | Beat 103.3% | $58.77M |
| Aug 7, 2025 | -0.02 | 0.00 | Beat 104.6% | $62.47M |
| May 8, 2025 | -0.03 | 0.03 | Beat 200.0% | $57.34M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 23, 2026 | 2026-10-23 16:06:26 | View |
| 8-K | Oct 14, 2026 | 2026-10-14 07:57:03 | View |
| 4 | Aug 10, 2026 | 2026-08-10 16:08:41 | View |
| S-8 | Aug 5, 2026 | 2026-08-05 16:57:59 | View |
| 10-Q | Aug 5, 2026 | 2026-08-05 16:10:36 | View |
| 8-K | Aug 5, 2026 | 2026-08-05 16:09:28 | View |
| 4 | Jul 1, 2026 | 2026-07-01 16:34:14 | View |
| 8-K | Jun 30, 2026 | 2026-06-30 08:05:11 | View |
| 4 | Jun 22, 2026 | 2026-06-22 16:24:48 | View |
| 4 | Jun 22, 2026 | 2026-06-22 16:23:29 | View |
Proxy statement (DEF 14A) disclosures